SG11201805900YA - Inhibition of allergic reaction using an il-33 inhibitor - Google Patents

Inhibition of allergic reaction using an il-33 inhibitor

Info

Publication number
SG11201805900YA
SG11201805900YA SG11201805900YA SG11201805900YA SG11201805900YA SG 11201805900Y A SG11201805900Y A SG 11201805900YA SG 11201805900Y A SG11201805900Y A SG 11201805900YA SG 11201805900Y A SG11201805900Y A SG 11201805900YA SG 11201805900Y A SG11201805900Y A SG 11201805900YA
Authority
SG
Singapore
Prior art keywords
international
california
pct
inhibitor
allergic reaction
Prior art date
Application number
SG11201805900YA
Inventor
Marco Londei
Original Assignee
Anaptysbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio Inc filed Critical Anaptysbio Inc
Publication of SG11201805900YA publication Critical patent/SG11201805900YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization MD 1111101110101011111 HO 11111 011101110101111101 010110111110111011# International Bureau 0.. .... .. (10) International Publication Number (43) International Publication Date ..... ..or::,,, WO 2017/124110 Al 20 July 2017 (20.07.2017) WIPO I PCT (51) International Patent Classification: A61K 39/395 (2006.01) C07K 16/24 (2006.01) A61P 37/08 (2006.01) C12N 15/13 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (21) International Application Number: PCT/US2017/013818 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (22) International Filing Date: 17 January 2017 (17.01.2017) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: 62/278,671 14 January 2016 (14.01.2016) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: ANAPTYSBIO, INC. [US/US]; 10421 Pacific Center Court, Suite 200, San Diego, California 92121 (US). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (72) Inventor: MARCO, Londei; 8875 Costa Verde Boulevard GW, KM, ML, MR, NE, SN, TD, TG). #702, San Diego, California 92122 (US). Published: (74) Agent: GASE, John L.; Leydig, Voit & Mayer, LTD, 1981 N. Broadway STE 310, Walnut Creek, California — with international search report (Art. 21(3)) before the expiration of the time limit for amending the 95131 (US). claims and to be republished in the event of receipt of Designated States (unless otherwise indicated, for every (81) amendments (Rule 48.2(h)) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, _ with sequence listing part of description (Rule 5.2(a)) Il © 11 11 7r N 1-1 IN 1-1 0 \" (54) Title: INHIBITION OF ALLERGIC REACTION USING AN IL-33 INHIBITOR (:) .,.. (57) : A method of inhibiting or preventing an allergic reaction, particularly to a food antigen, in a mammal comprising ad - .,. ministering to the mammal an IL-33 inhibitor.
SG11201805900YA 2016-01-14 2017-01-17 Inhibition of allergic reaction using an il-33 inhibitor SG11201805900YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662278671P 2016-01-14 2016-01-14
PCT/US2017/013818 WO2017124110A1 (en) 2016-01-14 2017-01-17 Inhibition of allergic reaction using an il-33 inhibitor

Publications (1)

Publication Number Publication Date
SG11201805900YA true SG11201805900YA (en) 2018-08-30

Family

ID=59311527

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201805900YA SG11201805900YA (en) 2016-01-14 2017-01-17 Inhibition of allergic reaction using an il-33 inhibitor
SG10202006699XA SG10202006699XA (en) 2016-01-14 2017-01-17 Inhibition of allergic reaction using an il-33 inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202006699XA SG10202006699XA (en) 2016-01-14 2017-01-17 Inhibition of allergic reaction using an il-33 inhibitor

Country Status (12)

Country Link
US (1) US20190016795A1 (en)
EP (1) EP3402521A4 (en)
JP (1) JP2019508382A (en)
KR (1) KR20180101533A (en)
CN (1) CN109475622A (en)
AU (1) AU2017208099A1 (en)
BR (1) BR112018014247A2 (en)
CA (1) CA3011547A1 (en)
EA (1) EA201891628A1 (en)
MX (1) MX2018008732A (en)
SG (2) SG11201805900YA (en)
WO (1) WO2017124110A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016009047A (en) 2014-01-10 2017-04-13 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33).
SG11201808693WA (en) 2016-04-27 2018-11-29 Pfizer Anti-il-33 antibodies, compositions, methods and uses thereof
JOP20190093A1 (en) 2016-10-28 2019-04-25 Lilly Co Eli Anti-il-33 antibodies and uses thereof
GB201712952D0 (en) * 2017-08-11 2017-09-27 Univ Edinburgh Immunomodulatory agent
WO2019074912A1 (en) * 2017-10-09 2019-04-18 Anaptysbio, Inc. Anti-il-33 therapy for atopic dermatitis
WO2019183639A1 (en) * 2018-03-23 2019-09-26 Anaptysbio, Inc. Inhibition of allergic reaction to peanut allergen using an il-33 inhibitor
TW202021983A (en) * 2018-09-21 2020-06-16 美商安納普提斯生物公司 Anti-il-33 therapy for eosinophilic asthma

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560530B1 (en) * 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
CA2685124A1 (en) * 2007-04-26 2008-11-06 Provost, Fellows And Scholars Of The College Of The Holy And Undivided T Rinity Of Queen Elizabeth Near Dublin Products for altering il-33 activity and methods therefor
US9212227B2 (en) * 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
JO3623B1 (en) * 2012-05-18 2020-08-27 Amgen Inc St2 antigen binding proteins
JO3532B1 (en) * 2013-03-13 2020-07-05 Regeneron Pharma Anti-il-33 antibodies and uses thereof
JP6404314B2 (en) * 2013-03-15 2018-10-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． IL-33 antagonists and uses thereof
KR101567758B1 (en) * 2013-10-17 2015-11-11 인하대학교 산학협력단 Composition for allergic diseases comprising anti-Siglec-8 antibody or anti-Siglec-F antibody, and anti-IL-22 antibody
EP3088517B1 (en) * 2013-12-26 2023-11-01 Mitsubishi Tanabe Pharma Corporation Human anti-il-33 neutralizing monoclonal antibody
MX2016009047A (en) * 2014-01-10 2017-04-13 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33).

Also Published As

Publication number Publication date
EP3402521A4 (en) 2019-11-20
MX2018008732A (en) 2018-12-06
AU2017208099A1 (en) 2018-08-09
EA201891628A1 (en) 2018-12-28
KR20180101533A (en) 2018-09-12
SG10202006699XA (en) 2020-08-28
WO2017124110A1 (en) 2017-07-20
CA3011547A1 (en) 2017-07-20
CN109475622A (en) 2019-03-15
BR112018014247A2 (en) 2018-12-18
EP3402521A1 (en) 2018-11-21
JP2019508382A (en) 2019-03-28
US20190016795A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
SG11201805900YA (en) Inhibition of allergic reaction using an il-33 inhibitor
SG11201908391XA (en) Methods for modulating an immune response
SG11201901442RA (en) Heart valve docking coils and systems
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201909949XA (en) Targeted immunotolerance
SG11201804647TA (en) Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
SG11201804934PA (en) Novel Compounds
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201908846SA (en) Susceptor assembly for inductively heating an aerosol-forming substrate
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201805001UA (en) Method of treating influenza a
SG11201901389XA (en) Combination therapy with glutaminase inhibitors
SG11201805311XA (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
SG11201808306PA (en) Treatment of cancer with tg02
SG11201808525UA (en) Anti-complement factor bb antibodies and uses thereof
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201909495PA (en) Combination cancer immunotherapy with pentaaza macrocyclic ring complex
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy
SG11201807596YA (en) Gitr antibodies, methods, and uses
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201900021PA (en) Methods and compositions for the treatment of cancer
SG11201805755SA (en) Methods of administering hepcidin
SG11201909882SA (en) Targeted neoepitope vectors and methods therefor